Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

f 2008 and if the results of this trial are positive, Cadence submitting a new drug application (NDA) for Omigard in the first half of 2009; data from the celgosivir Phase II extension protocol being available by the end of 2007; 4-week interim results from the Phase II viral kinetics combination study of celgosivir in approximately 10 treatment-naive patients in October 2007; submitting an IND in the US in the first quarter of 2008 for the future development of celgosivir; Cutanea Life Sciences completing the Phase II CLS001 rosacea clinical trial in 2007; our estimate of the probable royalties payable to the holders of the convertible royalty participation units; the Company continuing to advance its highest priority programs while operating within an annual burn rate of $11 million to $13 million; and the Company's financial resources being sufficient to fund operations into the third quarter of calendar 2008.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: Cadence's ability to enroll sufficient patients to complete the Omigard CLIRS trial; the adequacy of the CLIRS trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for Omigard; our ability to manage licensing opportunities; our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines; our partner Cutanea Life Sciences completing a Phase II CLS001 rosacea clinical trial in 2007; to and future expense levels being within our current expectations.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on c
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015 With recent advancements ... you the government, major companies are getting into the ... setting future mandates for renewable energy production, many homeowners ... , Solara Power is a new solar distribution company ... available that allow qualifying homeowners to enjoy the benefits ...
(Date:3/30/2015)... March 30, 2015  NuGene International, Inc. ("NuGene") ... NuGene BioPharma, Inc. has added another internationally recognized ... Guan is an internationally recognized researcher in bio-inspired ... education at Peking University, China ... the University of North Carolina, Chapel Hill. Following ...
(Date:3/30/2015)... OTTAWA , March 30, 2015 /CNW/ - A ... today on the salaries and demographic profiles of new ... "Opening the Door – Building Careers for New Grads ... Canada,s Research-Based Pharmaceutical Companies (Rx&D) and features ... federal Career Focus wage subsidy program from 2013 to ...
(Date:3/30/2015)... England , March 30, 2015 ... developing novel biological drugs to treat cancer, viral ... of Professor Sir John Bell , the ... Chairman of the Office for the Strategic Coordination ... with immediate effect.      (Photo: ...
Breaking Biology Technology:Solara Power Announces Residential Solar Power with No Up-Front Fees 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... NVAX ) and the University ... preclinical study of a Respiratory Syncytial Virus ("RSV"),vaccine ... from the, University of Massachusetts Medical School ... Paramyxovirus vaccines incorporating,certain Virus-Like-Particles ("VLPs"). This vaccine ...
... Calif., Dec. 9 BioMarin Pharmaceutical,Inc. (Nasdaq: ... its partner Merck Serono, a division,of Merck ... for,Kuvan(R) (sapropterin dihydrochloride) for the treatment of,hyperphenylalaninemia ... patients,from the European Commission. Merck Serono ...
... Corporation today announced favorable results from a Phase 1 ... candidates, for use during urological surgery. , ... of OMS201 enrolled patients undergoing endoscopic removal of urinary ... and safety of the drug product. The pharmacokinetic data ...
Cached Biology Technology:NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 2NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 3NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate 4Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group ... NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one ... feedback on their experience with the Wocket in multiple scenarios ... CVS, Whole Foods and other retailers, making both debit and ... Tuttle also says, "If the company meets their plans ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... and toes (metatarsals) and can be restricted in growth ... called brachydactyly type E (Greek for short fingers). Three ... group of Professor Friedrich C. Luft at the Experimental ... the Charit Medical Faculty and the Max Delbrck Center ...
... MIAMI November 5, 2012 -- A new study by ... Marine & Atmospheric Science uses Interferometric Synthetic Aperture Radar (InSAR) ... volcanoes in Indonesia,s west Sunda arc. Led by geophysicist Estelle ... that several volcanoes did in fact ,inflate, prior to eruptions ...
... Biomedical Research Institute scientists in San Antonio have developed ... for bioterror threats and accelerate the application of countermeasures., ... molecular magnets that bind to and hold on ... That will enable countermeasures to be selected and ...
Cached Biology News:New findings on gene regulation and bone development 2New findings on gene regulation and bone development 3New findings on gene regulation and bone development 4Taking the 'pulse' of volcanoes using satellite images 2Texas Biomed reports faster, more economical method for detecting bioterror threats 2
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
... Nucleon HT, 1 kit. Facilitates the ... paraffin-embedded sections and hard tissue requiring proteinase ... high quality DNA from 50 preparations of ... Category: DNA/RNA Synthesis & Purification, Purification and ...
Biology Products: